CD274 and neoplasm: Beyond tumour-intrinsic biomarkers associated with high TMB and a resultant increased immunogenic neoantigens repertoire, most identified biomarkers associated with anti-PD-(L)1 efficacy support the presence of a pre-existing adaptive immune response [237–241], suggesting that upregulation of immune-inhibitory pathways represent a central mechanism by which tumours escape immune surveillance [242, 243].